Synergistic Embolic Particle Systems
Legal Citation
Summary of the Inventive Concept
The present inventive concept integrates embolic particles with distinct technologies such as AI, IoT, blockchain, and new materials to create novel systems for occluding vascular defects and other luminal defects, enhancing treatment outcomes and patient care.
Background and Problem Solved
The original patent disclosed embolic particles with adjustable diameters for occluding vascular defects. However, these particles had limitations in terms of precise delivery, real-time monitoring, and personalized treatment. The new inventive concept addresses these limitations by synergistically combining the embolic particles with advanced technologies, enabling more effective and efficient treatments.
Detailed Description of the Inventive Concept
The inventive concept encompasses four distinct systems: 1) AI-powered embolic particle delivery, 2) IoT-enabled particle deployment and monitoring, 3) blockchain-secured data transmission for personalized medicine, and 4) novel material-coated microcatheters for enhanced particle delivery. Each system leverages the strengths of the embolic particles and the integrated technology to provide improved treatment outcomes. For instance, the AI-powered system optimizes particle size and delivery based on patient-specific data, while the IoT-enabled system provides real-time monitoring of particle deployment and aneurysm occlusion.
Novelty and Inventive Step
The new inventive concept introduces a paradigm shift in embolic particle technology by integrating distinct technologies to create novel systems that address the limitations of the original patent. The inventive step lies in the synergistic combination of these technologies, which enables more effective, efficient, and personalized treatments.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include integrating the embolic particles with other advanced technologies, such as robotics or nanotechnology, to further enhance treatment outcomes. Variations of the systems could also be developed for treating different types of luminal defects or for use in various medical specialties.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the medical device industry, particularly in the fields of interventional neuroradiology, cardiology, and urology. The integrated systems could be marketed as premium products, offering improved treatment outcomes and enhanced patient care.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61L24/06 |
| A | A61 | A61L24/001 |
| C | C08 | C08F222/385 |
| A | A61 | A61L2430/36 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical device technology, specifically interventional radiology and embolic particle systems for vascular occlusion, requiring expertise in materials science, medical device design, and minimally invasive treatment techniques
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or interventional radiologist with advanced degrees, familiar with medical device design, polymer chemistry, microcatheter technologies, and emerging medical technology integration strategies
Obviousness Rationale
A PHOSITA would recognize that integrating emerging technologies like AI, IoT, and advanced materials with existing embolic particle systems represents a predictable and incremental advancement in medical device design. The core functionality of the embolic particles remains consistent with the source patent, while the proposed technological integrations provide enhanced diagnostic and treatment capabilities using well-established engineering principles. These variations represent logical extensions of existing medical device innovation strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,694 |
|---|---|
| Title | Particles |
| Assignee(s) | MicroVention, Inc. |